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ARTICLE
Nova2 Interacts with a Cis-Acting Polymorphism to Inﬂuence
the Proportions of Drug-Responsive Splice Variants of SCN1A
Erin L. Heinzen,* Woohyun Yoon,* Sarah K. Tate, Arjune Sen, Nicholas W. Wood,
Sanjay M. Sisodiya, and David B. Goldstein
An intronic polymorphism in the SCN1A gene, which encodes a neuronal sodium-channel a subunit, has been previously
associated with the dosing of two commonly used antiepileptic drugs that elicit their pharmacologic action primarily at
this ion-channel subunit. This study sought to characterize the functional effects of this polymorphism on alternative
splicing of SCN1A and to explore the potential for modulating the drug response in the pharmacologically unfavorable
genotype by identiﬁcation of a splice modiﬁer acting on SCN1A. The effects of the genotype at the SCN1A IVS5N+5 GrA
polymorphism on SCN1A splice-variant proportions and the consequences of increased expression of splice modiﬁers
were investigated both in human temporal neocortex tissue and in a cellular minigene expression system. Quantitative
real-time polymerase chain reaction was used to quantify the amounts of SCN1A transcripts forms. We show that the
polymorphism has a dramatic effect on the proportions of neonate and adult alternative transcripts of SCN1A in adult
brain tissue and that the effect of the polymorphism also appears to be modiﬁed by Nova2 expression levels. A minigene
expression system conﬁrms both the effect of the polymorphism on transcript proportions and the role of Nova2 in the
regulation of splicing, with higher Nova2 expression increasing the proportion of the neonate form. A larger Nova2-
mediated effect was detected in the AA genotype that is associated with increased dose requirements. The effects of
Nova2 on modulation of the alternative splicing of 17 other neuronally expressed genes were investigated, and no effect
was observed. These ﬁndings emphasize the emerging role of genetic polymorphisms in modulation of drug effect and
illustrate both alternative splicing as a potential therapeutic target and the importance of considering the activity of
compounds at alternative splice forms of drug targets in screening programs.
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The study of pharmacogenetics has been conﬁned pre-
dominantly to the elucidation of genetic variation in pro-
cesses that control drug exposure, including drug-metab-
olizing enzymes and transporters. However, there is a
growing consensus that genetic variability in drug ab-
sorption, distribution, metabolism, and elimination plays
only a modest role in variability in treatment response
and that variation related to the mode of action of a drug
may often be as or more important.
Such genes, however, have not been thoroughly studied,
and, to date, there remain relatively few examples of poly-
morphisms in a pharmacologic target or downstream
pathway that contribute to variable drug response in hu-
mans. Perhaps the best documented example is the
VKORC1 gene (MIM 608547), which encodes a subunit of
the vitamin K epoxide reductase complex and the phar-
macological target for the commonly used anticoagulant
warfarin. A common polymorphism in this gene has been
signiﬁcantly associated with reduced warfarin dose.1 Al-
though not yet deﬁnitive, it now appears that the molec-
ular mechanism of this variation in warfarin response is
regulated at the transcriptional level.2
Another example of a common polymorphism that in-
ﬂuences drug response is one in SCN1A (MIM 182389),
the gene encoding the target of certain antiepileptic drugs.
The SCN1A IVS5N5GrA polymorphism (rs3812718, for-
merly SCN1A IVS4-91GrA) was shown to be signiﬁcantly
associated with maximum dose of both phenytoin and
carbamazepine in a cohort of patients with various forms
of epilepsy.3 Dosing in epilepsy, as well as in many other
therapeutic areas, often involves long periods of trial and
error and could beneﬁt from genetic predictors of dosing
requirements. In that study, Tate et al.3 found antiepileptic
drug dose to be lowest in patients with the GG genotype,
intermediate in those with the GA genotype, and highest
in those with the AA genotype. In a separate study by the
same authors that involved patients of Chinese ancestry,
an association was found between SCN1A IVS5N5 GrA
and phenytoin serum concentrations at maintenance dose,
again in the direction AArGArGG for highestrlowest
dose.4 The phenotype of serum concentration at main-
tenance dose was chosen, to eliminate the variation be-
tween drug doses and serum levels (which are likely to be
caused by pharmacokinetic factors) and therefore increase
the chance of detecting the effect of pharmacodynamic
variation in the drug target.
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Figure 1. Schematic of exons 4–6 of the SCN1A gene. A, The
adult (5A [red]) and neonatal (5N [green]) mRNA transcript forms
of exon 5. The location of the SCN1A IVS5N5 GrA polymorphism
(rs3812718) is indicated by the red star located in the 5′ splice-
donor site after exon 5N. The blue line stretching from intron 4
to intron 5 indicates the gene region covered by the minigene
construct. B, Sequence of the minigene construct with exon 5N
(highlighted in green) and exon 5A (highlighted in red). The nine
putative Nova-binding sites ([T/C]CA[T/C])5 are highlighted in yel-
low. Highlighted in blue are SNPs that are located in the minigene
construct (in order of appearance in the sequence: rs2195144
[ArG], rs2217199 [TrC], rs3812719 [GrT], and rs3812718
[GrA]).
Interestingly, SCN1A IVS5N5 GrA is located in the
consensus-site sequence located after the neonatal form
of exon 5 (exon 5N) of the SCN1A gene (ﬁg. 1).3 Collec-
tively, this GrA change, which notably is a frequent mu-
tation associated with mammalian disease,6 results in the
disruption of the conserved consensus-site sequence,
which would theoretically result in a possibly weaker 5′
splice site.7 Consistent with this theory, preliminary data
reported by Tate et al.3 suggest that the SCN1A IVS5N5
GrA polymorphism may control the proportion of the
two transcript forms in adults. This exon 5 alternative
splicing event is conserved across all neuronally expressed
sodium channels.8,9 Although not well studied for SCN1A,
there is extensive evidence of the developmental regula-
tion of this splicing event at other neuronally expressed
sodium channels.8,9 The sequence conservation across
neuronally expressed sodium channels suggests that this
also may occur for SCN1A, as indicated by semiquanti-
tative assays reported by Tate et al.3 The molecular control
of developmentally regulated sodium-channel alternative
splicing is unknown.
Recently, several neuronally expressed splice-modiﬁer
proteins have been identiﬁed, including neuro-oncologi-
cal ventral antigen 1 and 2 (Nova1 and Nova2, respec-
tively) and sodium channel modiﬁer 1 (Scnm1).10–12 It is
possible that these neuronally expressed splice-modiﬁer
proteins may contribute to the alternative splicing of ex-
on 5 of SCN1A. Importantly, the genomic region in and
around exon 5 contains several putative Nova-binding
sites (ﬁg. 1), suggesting a possible role of Nova proteins
in regulation of transcript splicing.5
Given the association of this SCN1A polymorphism
with altered doses of antiepileptic drugs, it is possible that
drug doses found clinically may be inﬂuenced by the pro-
portion of SCN1A transcripts in the neonatal form. Elu-
cidating the genetic and molecular process that regulates
this event not only may help in the prediction of how
patients may respond to particular antiepileptic drugs but
also may reveal a means for driving the splice-variant tran-
script proportion to the drug-responsive state in patients
with the unfavorable (AA) genotype. Therefore, this study
sought to quantify the effect of SCN1A IVS5N5 GrA
genotype on exon 5 splice-variant proportions and to de-
termine the effects of neuronally expressed splice-modiﬁer
proteins on the controlling of this splice event.
Material and Methods
Subjects
This study was approved by the Joint Research Ethics Committee
of the Institute of Neurology and the National Hospital for Neu-
rology andNeurosurgery and by theDukeUniversity Institutional
Review Board. All patients gave written informed consent for use
of resected brain tissue for research. Forty-three temporal neo-
cortical tissue samples were obtained frommaterial resected from
patients who underwent therapeutic surgery for drug-resistant
mesial temporal lobe epilepsy, in accordance with routine clinical
protocols. All tissue used for research was surplus to diagnostic
requirements. Subjects were aged 18–60 years, and the group con-
sisted of 15 men and 28 women. The population of patients with
mesial temporal lobe epilepsy was the same as in the 2005 study
by Tate et al.,3 although random subjects were selected for both
studies (thus it is possible that there may be an overlap of subjects
in this study and subjects in the study by Tate et al.). All subjects
had received a diagnosis of hippocampal sclerosis that was con-
ﬁrmed histologically. The hippocampal tissue was excluded from
analysis because of potential confounding issues of neuronal loss.
All tissue was ﬂash frozen in liquid nitrogen and was stored at
80C until use.
Twenty-nine nonepileptic control temporal cortex tissue sam-
ples were obtained through the Kathleen Price Bryan Alzheimer’s
Disease Brain Bank at Duke University. All patients gave written
informed consent for use of the brain tissue for research. The
control tissue was collected postmortem (time to collection
ranged from 1 to 30 h postmortem, with controlling for agonal
state). Subjects were aged 56–90 years, and the group consisted
of 14 men and 15 women. Ethical permission for the use of this
tissue was provided by Duke University Medical Center Institu-
tional Review Board.
DNA Extraction and Genotyping
DNA was extracted using the Trizol method (Invitrogen), per the
manufacturer’s instructions. DNA quantity and quality were as-
sessed spectrophotometrically.
Samples were genotyped for the SCN1A IVS5N5 GrA poly-
morphism (rs3812718) by use of a custom designed TaqMan-
based allelic discrimination assay (Applied Biosystems). Assay
primer and ﬂuorescently labeled probe sequences were as follows
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Table 1. Alternative Splicing Events
in Ion-Channel Genes That Were
Screened for Nova2-Mediated
Regulation
Gene
GenBank Accession Number
for Splice Form
Common Variant
CACNA1A NM_023035 BE972738
CACNA1B NM_000718 M94173
CACNA1G NM_018896 NM_198376
CACNB1 NM_000723 NM_199247
CACNB4 NM_000726 AY054985
CLCN7 NM_001287 AK096963
FXYD6 NM_022003 BP372334
GRIA1 NM_000827 A46050
GRIA3 NM_007325 NM_000828
HTR3A NM_000869 BG341613
KCNJ15 NM_170736 CQ732921
KCNK1 NM_002245 AV733795
KCNN1 NM_002248 BM718136
KCNN2 NM_021614 BG769522
KCNQ2 NM_004518 AY358189
MCOLN1 NM_020533 CA489568
SCN1A NM_006920 CQ727958
(all are 5′r3′): forward primer, TTTCAGAGTCTTGAGAGCTTTGA-
AAA; reverse primer, TGTGACGTACCTGTAATAGGGAGTTC; G
probe, FAM-AATTCCAGGTAAGAAGTGA-MGB; and A probe,
VIC-AATTCCAGGTAAAAAGTGA-MGB. Assay conditions were in
accordance with manufacturers’ standard protocols. Fluorescence
outputs were quantiﬁed in real time by use of a 7900HT Fast Real
Time PCR System, and the data were analyzed using SDS software,
version 2.2.2 (Applied Biosystems).
RNA Extraction and cDNA Generation
Total RNA was extracted from brain tissue by use of the RNeasy
Lipid Tissue Puriﬁcation Kit (Qiagen), in accordance with the
manufacturer’s instructions. RNA from cells was extracted using
the RNeasy Puriﬁcation Kit (Qiagen). The resulting RNA was
quantiﬁed spectrophotometrically, and 1 mg of total RNA was
reverse transcribed into cDNA by use of a High Capacity cDNA
Synthesis Kit (Applied Biosystems), in accordance with product
instructions.
Plasmid and Minigene Constructs
An Exon Trapping system (Gibco) was used to assess the genetic
and molecular control of the alternative splicing of exon 5N and
5A in SCN1A. A genomic DNA fragment of 696 bp containing
exon 5N and 5A of SCN1Awas PCR ampliﬁed using a primer set—
forward primer, GATCGAATTCCCAGAGTGACAACAAGGGTGT,
and reverse primer, GATCGGATCCGGTCACCTTGACCTCAAAT-
TACA—and was subcloned into a pSPL3 vector. The A and G
forms of the minigene were obtained by separate ampliﬁcation
of homozygous individuals. SCNm1 (MIM 608095),NOVA1 (MIM
602157), and NOVA2 (MIM 601991) cDNA with a full-lengthORF
was PCR ampliﬁed with cDNAs from neuroblastoma cells, SK-N-
BE(2), by use of primer sets (all are 5′r3′): SCNm1 forward primer,
GATCAGATCTATGTCTTTCAAGAGGGAAGGA; SCNm1 reverse
primer, GATCGAATTCTCAGTCCAAGGGGAGATCAGG; NOVA1
forward primer, ATTACTCGAGAACATGATGGCGGCAGCTCC;
NOVA1 reverse primer, ATTAGGTACCTCAACCCACTTTCTGAG-
GATT; NOVA2 forward primer, TATTACTCGAGATGGAGCCCGA-
GGCCCCGGAT; and NOVA2 reverse primer, ATTAGGTACCCAG-
GCCTCATCCCACTTTCT. Total RNA was extracted from the
SK-N-BE(2) cells and was converted to cDNA by use of a High-
Capacity cDNA Archive Kit (Applied Biosystems) forNOVA2 clon-
ing. PCR was performed with a high-ﬁdelity DNA polymerase,
Platinum Pfx (Invitrogen). The PCR product was subcloned into
pcDNA3.1 (Invitrogen), with an N-terminal hemagglutinin (HA)
tag. All the sequences were veriﬁed by DNA sequencing.
To conﬁrm the causal polymorphism of the observed effects in
the minigene system, the SCN1A IVS5N5 GrA polymorphism
(rs3812718) was introduced in the G construct by use of a
QuikChange XL Site-Directed Mutagenesis Kit (Stratagene).
Cell Transfection
HEK293 cells were grown to 80% conﬂuence in 6-well plates. The
cells were transfected with 0.1 mg of SCN1A minigene (A, G, or
equal quantities of A and G) and varying amounts of NOVA2
plasmids by use of Lipofectamine 2000 (Invitrogen), in accor-
dance with the manufacturer’s guide. After 48 h, cells were har-
vested for RNA extraction and western-blot analyses. The same
experimental designwas employed for transfection of SCNm1 and
NOVA1 plasmids; however, this was limited to a single transfec-
tion of 1 mg.
Real-Time PCR
TaqMan-based real-time PCR was used to determine the per-
centage of SCN1A transcripts containing exon 5N and 5A. Assays
were custom designed through Applied Biosystems, and primers
or probe sequences were used in these assays as follows (all are
5′r3′). For SCN1A 5A transcript quantiﬁcation in human brain
tissue, forward primer AACTGGCTCGATTTCACTGTCATTA,
reverse primer ATTGCCCAGGTCCACAAACT, and probe FAM-
CTGTGACGTACGCAAATG-NFQ were used. For SCN1A 5N tran-
script quantiﬁcation, forward primer TGGCTCGATTTCACTGTC-
ATTACAT, reverse primer TCTGAAAGTGCGAAGAGCTGAAAA,
and probe FAM-CCTAGGTTTACAAATTCTG-NFQ were used. For
SCN1A 5A transcript quantiﬁcation in HEK293 cells, forward
primer GTGAACTGCACTGTGACAAGCTGC, reverse primer
CACCTGAGGAGTGAATTGGTCG, and probe FAM-CCGAGCAT-
TGAAGACGA-NFQ were used. For SCN1A 5N transcript quanti-
ﬁcation, forward primer GTGAACTGCACTGTGACAAGCTGC,
reverse primer TCTGAAAGTGCGAAGAGCTGAAAA, and probe
FAM-CCTAGGTTTACAAATTCTG-NFQ were used. SCNm1, NOVA1,
NOVA2, and b-actin mRNA expression levels were quantiﬁed us-
ing commercially available TaqMan assays (Applied Biosystems).
Fluorescence outputs were quantiﬁed in real time by use of a
7900HT Fast Real Time PCR System, and the data were analyzed
using SDS software, version 2.2.2 (Applied Biosystems). In sub-
jects with the AA genotype, the output data often were below
the limit of detection for the 5N assay. In these cases, the per-
centage of SCN1A transcripts containing exon 5N was considered
to be zero.
The effect of Nova2 on alternative splicing events in 17 ion-
channel genes (splicing events are deﬁned in table 1) was inves-
tigated in cells transfected with 0.1 mg of SCN1A minigene with
and without 1 mg NOVA2 cDNA transfection (the same prepara-
tion was used for investigation of the effects of Nova2 on SCN1A
exon 5 splicing). TaqMan-based real-time PCR assays were used
to quantify splice-variant ratios (variant:common transcript
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Figure 2. Evidence of the genetic control of SCN1A exon 5 al-
ternative splicing in human brain tissue. A, Correlation of the
SCN1A IVS5N5 GrA genotype with the percentage of transcripts
containing neonatal exon 5N in the temporal neocortex of control
tissue (unblackened circles) and mesial temporal lobe epileptic
brain tissue (blackened circles). by ANOVA for mesial tem-P ! .001
poral lobe epilepsy and control samples combined, and P ! .001
by ANOVA for separate analyses of mesial temporal lobe epilepsy
and control samples. By Tukey post hoc statistical analysis, P !
for AA versus AG, for AG versus GG, and for.001 P ! .001 P ! .001
AA versus GG. B, Difference in the percentage of transcripts con-
taining neonatal exon 5N in the temporal neocortex of control
samples and mesial temporal lobe epileptic brain tissue. Data are
presented as mean  SEM. by Student’s t test for com-P ! .05
parison with control.
forms, as deﬁned in table 1) by targeting unique exon-exon
boundaries.
Western-Blot Analysis
Protein was extracted with 2% SDS from cell pellet. Protein was
separated on an NuPAGE 4%–12% Bis-Tris gel (Invitrogen). The
gel was blotted to nitrocellulose membrane (BioRad). The
membrane was blocked with 5% skimmilk. Then, the membrane
was incubated with rabbit anti-HA antibody (1:500 [Abcam])
overnight at 4C and subsequently was incubated with horserad-
ish peroxidase–conjugated anti-rabbit antibody (1:5,000 [Amer-
sham]) for 1 h at room temperature. The signal was detected by
Amersham ECL kit. Rabbit anti–b-actin antibody (1:2,000 [Ab-
cam]) was used for a loading control. ImageJ software was used
to perform densitometric analysis.
Data Analysis
One-way analysis of variance (ANOVA) was used to determine
the statistical signiﬁcance of the SCN1A exon 5N splice variant
compared with SCN1A IVS5N5 GrA genotype correlation in
human brain tissue. Statistical analyseswere performed separately
in control and mesial temporal lobe epilepsy samples, in addition
to a combined subject analysis. Tukey post hoc tests were used
to determine the statistically signiﬁcant differences between splic-
ing proportions in the three genotype groups.
The effects of NOVA2 mRNA expression (NOVA2) on the per-
centage of SCN1A mRNA transcripts containing exon 5N (SCN1A
5N%) were ﬁt to a sigmoidal Emax model deﬁned as follows:
gE # E(NOVA2 )max 50SCN1A 5N%p 5N%  , (1)0 g gE(NOVA2 )NOVA250
where Emax is the maximum NOVA2-mediated change in SCN1A
5N%, E( ) is amount of NOVA2 needed to elicit one-halfgNOVA250
the maximum effect on SCN1A 5N%, g is the shape factor gov-
erning the relationship between SCN1A 5N% and NOVA2 mRNA
expression, and 5N%0 is the percentage of transcripts containing
exon 5N in the presence of no or very low quantities of NOVA2.
Linear regressionwas used to assess the effects of splice-modiﬁer
protein mRNA expression on the proportion of SCN1A transcripts
for all subjects and for the individual genotypes. Student’s t test
was used to compare splice-variant ratios of ion-channel genes
in HEK293 cells transfected with SCN1A minigene and in the
presence and absence of 1-mg NOVA2 cDNA transfection (np 3
independent replications per group).
Results
In human brain tissue, the SCN1A IVS5N5 GrA poly-
morphism had a substantial effect on the percentage of
transcripts containing exon 5N (neonatal form) of SCN1A
(ﬁg. 2A). Individuals with the AA genotype had a mean
(SEM) of of SCN1A transcripts in the neo-0.7% 1%
natal form, whereas subjects with the GG genotype had
of transcripts containing exon 5N. The G allele41% 9%
elicited a dominant effect, with those with the AG ge-
notype having of transcripts in the neonatal28% 4%
form. The presence or absence of a history of temporal
lobe epilepsy did not affect the correlation between ge-
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Figure 3. Percentage of SCN1A mRNA transcripts containing exon
5N graphed versus NOVA2 mRNA expression (normalized to b-actin
expression) for controls and subjects with mesial temporal lobe
epilepsy with the AA (triangles), AG (circles), and GG (squares)
genotypes at the SCN1A IVS5N5 GrA polymorphism. NOVA2
mRNA expression correlates with the extent of SCN1A exon 5 splic-
ing for the AA genotype in human brain tissue. Lines indicate the
ﬁt of a linear regression model to the data for each genotype
subgroup.
Figure 4. Evidence of the genetic control of SCN1A exon 5 al-
ternative splicing in a minigene construct. Shown is the change
in the percentage of exon 5N expression with SCN1A IVS5N5
GrA genotype in HEK293 cells transfected with the genomic DNA
fragment containing the G, A, or A and G alleles (1 mg plasmid in
total). Data are presented as the mean of two independent rep-
lications (values for independent observations are superimposed
by use of dashes [–]).
notype and the alternative splicing event. However, the
magnitude of the proportion of SCN1A neonatal tran-
scripts was slightly altered in the disease state, with a trend
toward a lower percentage of transcripts containing exon
5N in patients withmesial temporal lobe epilepsy (ﬁg. 2B).
We also investigated a possible role for neuronally ex-
pressed splice-modiﬁer proteins—Nova1, Nova2, and
Scnm1—in controlling the SCN1A exon 5 splicing event,
by assessing the correlation between the percentage of
transcripts containing exon 5N and the mRNA expression
within individual genotypes. We found no effect of Nova1
and Scnm1 on modulation of the SCN1A exon 5 splicing
event, collectively or for individual genotypes. Although
no NOVA2-mediated modulation of SCN1A exon 5 splic-
ing was detected when all subjects were evaluated, a sta-
tistically signiﬁcant correlation (uncorrected for multiple
testing) was observed in human brain tissue between
NOVA2 mRNA expression and the percentage of SCN1A
transcripts containing exon 5N for the AA genotype (ﬁg.
3). NOVA2 mRNA expression was equivalent in both me-
sial temporal lobe epilepsy and control brain tissue, and
a similar correlation was observed in both experimental
groups (data not shown).
We used a minigene expression system to conﬁrm a
causal relationship between these correlations observed in
human adult brain tissue. First, we tested the role of the
SCN1A IVS5N5 GrA polymorphism. In this cellular sys-
tem, the experimentally simulated GG genotype resulted
in 51% of transcripts containing exon 5N, whereas the
percentage was signiﬁcantly reduced for the AA genotype,
to 7% (ﬁg. 4). The AG genotype resulted in 40% of tran-
scripts being in the neonatal form (ﬁg. 4); however, we
note that we did not quantify the true copy numbers of
the A and G alleles in this study.
Because of the presence of other SNPs in the minigene
construct (ﬁg. 1), we also performed mutagenesis studies
to conﬁrm that the SCN1A IVS5N5 GrA polymorphism
was eliciting the observed splicing changes and that the
alternations were not due, in whole or in part, to other
polymorphisms in the minigene construct. Direct se-
quencing of the G minigene construct revealed the ref-
erence sequence indicated in ﬁgure 1. The A construct had
the alternate sequence at all the SNP locations (rs2195144
[ArG], rs2217199 [TrC], rs3812719 [GrT], and rs3812718
[GrA]). To conﬁrm that the SCN1A IVS5N5 GrA poly-
morphism is the causal SNP in the minigene system, we
mutated the SCN1A IVS5N5 GrA polymorphism in the
G construct to the A form (at the IVS5N5 site) and tested
the effects of this change on the percentage of transcripts
containing exon 5N. This experiment revealed no statis-
tical difference in transcripts containing exon 5N between
the original AAminigene system and the GG-mutated sys-
tem (data not shown). These ﬁndings conﬁrm that the
SCN1A IVS5N5 GrA polymorphism is, in fact, the casual
variant in the modulation of the alterations in SCN1A
exon 5 splicing.
Next, we tested how overexpression of the common
neuronally expressed splice-modiﬁer proteins Scnm1,
Nova1, and Nova2 inﬂuences SCN1A splicing. Overex-
pression of neither Scnm1 nor Nova1 showed any effects
on SCN1A exon 5 alternative splicing in the minigene
cellular system investigated here (data not shown). How-
ever, increasing Nova2 decreased the quantity of SCN1A
transcripts containing the adult form of exon 5 while it
simultaneously increased the number of transcripts con-
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Figure 5. Top panels, Change in the percentage of SCN1A transcripts containing exon 5N in the presence of increasing NOVA2 mRNA
expression in the HEK293 minigene construct with genotype AA (A) or GG (B) at the SCN1A IVS5N5 GrA polymorphism. Lines indicate
the ﬁt of the Emax model in equation (1) to the data. Bottom panels, Western blot of the change in HA-tagged Nova2 protein expression
with increasing amounts of NOVA2 plasmid in the HEK293 cells. Nova2 modulates SCN1A splicing in the AA genotype to a greater extent
than in the GG genotype.
taining the neonatal form. Overall, this translated into
Nova2 increasing the percentage of SCN1A transcripts
containing exon 5N (ﬁg. 5). However, the effects of Nova2
varied for the different SCN1A IVS5N5 GrA genotypes.
For the GG genotype, NOVA2 mRNA expression at the
observed maximum elicited an ∼2.5-fold increase in the
proportion of SCN1A transcripts containing exon 5N,
whereas, for the AA genotype, the expression change pro-
duced an ∼20-fold change in the splicing event. Similar
to the observations in human brain tissue, these ﬁndings
support a greater effect of Nova2 in the AA genotype.
We note that, in these experiments, the maximum
changes in splicing elicited by Nova2 in the AA genotype
were predicted only and were not directly observed (i.e.,
an experimentally derived maximum plateau of effect was
not obtained in these experiments) (ﬁg. 5). Despite the
failure to reach the plateau, a much larger change from
baseline in SCN1A alternative splicing was observed, de-
spite a lower maximum-observed increase in NOVA2
mRNA expression in the AA minigene cellular system. In-
creases in NOVA2 mRNA expression were associated with
increases in protein expression for both genotypes (ﬁg. 5),
which is consistent with the hypothesis that expression
of the splice-modiﬁer protein is modulating the observed
effects on SCN1A alternative splicing. Importantly, we em-
phasize that, with modulation of Nova2 expression, the
SCN1A exon 5 splice-variant percentage in the AA system
approached that observed for the GGminigene expressing
endogenous levels of NOVA2 mRNA (ﬁg. 5).
Finally, we tested the speciﬁcity of Nova2-mediated al-
ternative splicing by evaluating the effects of increases
in expression of this protein on modulation of splicing
events in 17 neuronally expressed ion-channels genes.We
found that Nova2 exhibited no effect on splice-variant
ratios for any of the 17 alternative splicing events deﬁned
in table 1 (data not shown).
Discussion
The SCN1A IVS5N5 GrA polymorphism, located in the
splice-donor site of exon 5N, had a striking effect on the
percentage of transcripts in the neonatal form of the
SCN1A gene in adults with and without epilepsy (ﬁg. 2A).
In those individuals with the GG genotype, up to 50% of
the transcripts include the neonatal version of exon 5,
compared with an often undetectable level of the neonatal
version in some subjects with the AA genotype. This cor-
relation reveals a statistically signiﬁcant increase in exon
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5 splicing between the AG and GG genotypes; however,
the magnitude of the change is less between the AG and
GG genotypes compared with that between the AA and
AG genotypes both in vivo and in vitro (ﬁgs. 2A and 4,
respectively). It is unclear why the G allele appears to elicit
a dominant effect on exon 5 splicing (ﬁgs. 2A and 4).
The association was observed clearly both in autopsy
samples from individuals who do not have known neu-
rological conditions and in resection tissue samples from
patients with a history of refractory temporal lobe epilepsy
(ﬁg. 2A), providing evidence that this splice variation is
likely to be largely genetically controlled, rather than a
seizure-induced event. Tate et al.3 reported a very modest
effect of genotype on SCN1A exon 5 alternative splicing
in patient temporal neocortical tissue only, not in control
brain tissue.3 The discrepancy could be attributed to the
lack of quantitative real-time PCR in the original study,
coupled with the comparatively smaller sample sizes eval-
uated. It is also possible that the difference may simply
be due to a different population of control subjects used
in this study. We note that animal models of epilepsy also
indicate an association between increased exon 5N levels
and seizures,13,14 which is not apparent in our samples by
the quantitative assays used here. In fact, in our samples,
there was a slightly reduced percentage of neonatal tran-
scripts in the brain tissue collected from mesial temporal
lobe epilepsy for each genotype group (ﬁg. 2B). This op-
posing ﬁnding may simply be due to differences between
the animal models and humans. Although additional
work is needed to establish the role of seizures in medi-
ating SCN1A exon 5 alternative splicing, our data clearly
show that the genotype predominantly drives this alter-
native splicing event, regardless of disease status.
Consistent with the correlation between SCN1A IVS5N5
GrA genotype and alternative transcript splicing in hu-
man brain tissue, the exon 5N and 5A minigene system
also demonstrated that the expression level of exon 5N
was directly affected by the genotype (ﬁg. 4). The pro-
portion found is strikingly similar to the data fromhuman
samples. These data reveal virtually no change in the level
of exon 5A expression, indicating that the effect of the
SCN1A IVS5N5 GrA polymorphism appears to be
mainly the result of increased exon 5N expression, a ﬁnd-
ing that also is consistent with the observations in hu-
mans. The SCN1A IVS5N5GrApolymorphism is located
6 bases into the intron in the 5′ splice site following exon
5N (ﬁg. 1). The guanine base at this nucleotide position
is highly conserved, with an estimated presence of 75%–
86% in human introns, whereas the adenine nucleotide
at this base position is far less common, with a presence
of ∼5%–11%.15 Given that the SCN1A IVS5N5GrApoly-
morphism causes a change from a highly conserved se-
quence to a lesser conserved sequence, it was not unex-
pected that a functionally weaker 5′ splice site at exon 5N
was seen in the presence of this change.
This unambiguous evidence of genetic control of a splic-
ing event in the SCN1A gene, in combination with the
new data further supporting genotype dependency of
phenytoin dose in patients with epilepsy,4 provides an
example of a functionally signiﬁcant genetic polymor-
phism that appears to directly inﬂuence the therapeutic
dose of antiepileptic medications and could have other
currently unknown phenotypic consequences.
The genetically controlled splicing variation and, con-
sequently, the altered dose requirements of carbamazepine
and phenytoin in humans could be the result of the prod-
uct of transcript variant of the SCN1A gene producing
altered electrical signaling in patients with epilepsy (i.e.,
epilepsy is worse in patients with the AA genotype, there-
fore requiring higher doses of antiepileptic medication to
effectively control the seizures). However, our observa-
tions also could be the result of altered pharmacology of
the antiepileptic drugs in the presence of the different
genotypes (i.e., altered potency and/or efﬁcacy of the
drugs at the SCN1A gene product). Consistent with the
latter possibility, an analogous functional splicing altera-
tion in the sodium-channel gene of theGermancockroach
has been reported to cause altered sensitivity to delta-
methrin.16,17 Furthermore, we cannot rule out the possi-
bility that the electrical properties of SCN1A at baseline
and in the presence of drugs differ in the presence of al-
tered transcript-variant quantities. To address this impor-
tant question, future work will focus on identifying the
functional differences between the products of the SCN1A
exon 5N and 5A transcripts in the absence and presence
of drugs.
In addition to the effects of the SCN1A polymorphism,
we also have documented an important role of Nova2 in
modulating the proportion of SCN1A alternative tran-
scripts. Because the two transcripts appear to result in dif-
ferent pharmacological properties, this work clearly high-
lights the potential therapeutic importance of control of
splice variation. For example, because the neonate form
appears to be more responsive to some antiepileptic drugs,
it would seem possible, in principle, to make some forms
of epilepsy more easily treatable by increasing the pro-
portion of the neonate transcript through manipulation
of NOVA2 expression or other modiﬁer genes.
Given these ﬁndings, Nova2 may, in the future, prove
to be a drug target for improvement of pharmacologic
responsiveness in a population of patients with refractory
epilepsy. However, we note that Nova2 has been shown
to modulate numerous alternative splicing events in
vivo,18 and it could be argued that such a strategy may
suffer from extensive nonspeciﬁc effects. As a preliminary
step toward evaluating the generality of NOVA2 effects on
neuronal splicing, we looked at 17 alternative splicing
events in ion-channel genes in the presence and absence
of increases in Nova2 expression. Of these selected alter-
native splicing events (table 1), none exhibited Nova2-
mediated alternative splicing, although additional work is
needed to evaluate comprehensively the speciﬁcity of
Nova2 in modulating neuronal splicing in humans. These
data highlight a speciﬁc regulatory role of Nova2 in con-
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trolling a clinically signiﬁcant alternative splicing of
SCN1A and provide novel avenues to pursue in the at-
tempt to understand and regulate genetic response to
medications.
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